PTAB Wrong To Reject Flu Med IP, Fed. Circ. Hears
GlaxoSmithKline pressed a Federal Circuit panel Tuesday to revive an application for an inhalation treatment for the influenza virus that was rejected by the Patent Trial and Appeals Board, arguing all...To view the full article, register now.
Already a subscriber? Click here to view full article